Gosset Amygdala Neurosciences General Information
Amygdala Neurosciences has advanced two proprietary small molecule ALDH2 inhibitors—ANS‑6637 and ANS‑858—for the treatment of substance use disorders. ANS‑6637 has completed extensive Phase 1 studies in over 150 subjects and entered multiple NIH-funded Phase 2 trials targeting alcohol, opioid, nicotine, and cocaine dependence. Preclinical data show reduction in drug-seeking behavior across several addiction models. The company recently selected ANS‑858 as its next clinical candidate with IND-enabling work underway for first-in-human studies targeting craving reduction in SUDs.[3][6][8] Early clinical results indicate safety/tolerability with ongoing efficacy evaluation. Pipeline breadth: At least two main programs identified.
Contact Information
United States
Drug Pipeline
Key Partnerships
National Institutes of Health/NIAAA/NIH HEAL Initiative, Institute of Human Virology at University of Maryland School of Medicine, NIH Clinical Center [8][10]
Amygdala Neurosciences Funding
No funding data available